XML 32 R68.htm IDEA: XBRL DOCUMENT
v3.20.1

Segment Reporting - Sales of Company's Products (Details) - USD ($) $ in Millions | 3 Months Ended
--- | ---
Mar. 31, 2020 | Mar. 31, 2019
Segment Reporting Information [Line Items] |  |
Sales | $ 12,057 | $ 10,816
Proceeds from Sale of Intangible Assets | 75 | 15
Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Sales | 11,892 | 10,727
Other |  |
Segment Reporting Information [Line Items] |  |
Sales | 165 | 89
United States |  |
Segment Reporting Information [Line Items] |  |
Sales | 5,137 | 4,555
United States | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Sales | 5,121 | 4,548
United States | Other |  |
Segment Reporting Information [Line Items] |  |
Sales | 16 | 7
International |  |
Segment Reporting Information [Line Items] |  |
Sales | 6,920 | 6,261
International | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Sales | 6,771 | 6,179
International | Other |  |
Segment Reporting Information [Line Items] |  |
Sales | 149 | 82
Total Pharmaceutical segment sales | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Sales | 10,655 | 9,663
Total Pharmaceutical segment sales | Operating Segments | Keytruda |  |
Segment Reporting Information [Line Items] |  |
Sales | 3,284 | 2,269
Total Pharmaceutical segment sales | Operating Segments | Alliance revenue - Lynparza (1) |  |
Segment Reporting Information [Line Items] |  |
Sales | 145 | 79
Total Pharmaceutical segment sales | Operating Segments | Alliance revenue - Lenvima (1) |  |
Segment Reporting Information [Line Items] |  |
Sales | 128 | 74
Total Pharmaceutical segment sales | Operating Segments | Emend |  |
Segment Reporting Information [Line Items] |  |
Sales | 43 | 117
Total Pharmaceutical segment sales | Operating Segments | Gardasil/Gardasil 9 |  |
Segment Reporting Information [Line Items] |  |
Sales | 1,097 | 838
Total Pharmaceutical segment sales | Operating Segments | ProQuad/M-M-R II/Varivax |  |
Segment Reporting Information [Line Items] |  |
Sales | 435 | 496
Total Pharmaceutical segment sales | Operating Segments | Pneumovax 23 |  |
Segment Reporting Information [Line Items] |  |
Sales | 256 | 185
Total Pharmaceutical segment sales | Operating Segments | RotaTeq |  |
Segment Reporting Information [Line Items] |  |
Sales | 222 | 211
Total Pharmaceutical segment sales | Operating Segments | Vaqta |  |
Segment Reporting Information [Line Items] |  |
Sales | 60 | 47
Total Pharmaceutical segment sales | Operating Segments | Bridion |  |
Segment Reporting Information [Line Items] |  |
Sales | 299 | 255
Total Pharmaceutical segment sales | Operating Segments | Noxafil |  |
Segment Reporting Information [Line Items] |  |
Sales | 94 | 190
Total Pharmaceutical segment sales | Operating Segments | Invanz |  |
Segment Reporting Information [Line Items] |  |
Sales | 64 | 72
Total Pharmaceutical segment sales | Operating Segments | Prevymis |  |
Segment Reporting Information [Line Items] |  |
Sales | 60 | 32
Total Pharmaceutical segment sales | Operating Segments | Cancidas |  |
Segment Reporting Information [Line Items] |  |
Sales | 55 | 61
Total Pharmaceutical segment sales | Operating Segments | Primaxin |  |
Segment Reporting Information [Line Items] |  |
Sales | 51 | 59
Total Pharmaceutical segment sales | Operating Segments | Cubicin |  |
Segment Reporting Information [Line Items] |  |
Sales | 46 | 88
Total Pharmaceutical segment sales | Operating Segments | Zerbaxa |  |
Segment Reporting Information [Line Items] |  |
Sales | 37 | 26
Total Pharmaceutical segment sales | Operating Segments | Simponi |  |
Segment Reporting Information [Line Items] |  |
Sales | 215 | 208
Total Pharmaceutical segment sales | Operating Segments | Remicade |  |
Segment Reporting Information [Line Items] |  |
Sales | 88 | 123
Total Pharmaceutical segment sales | Operating Segments | Belsomra |  |
Segment Reporting Information [Line Items] |  |
Sales | 79 | 67
Total Pharmaceutical segment sales | Operating Segments | Isentress/Isentress HD |  |
Segment Reporting Information [Line Items] |  |
Sales | 245 | 255
Total Pharmaceutical segment sales | Operating Segments | Zepatier |  |
Segment Reporting Information [Line Items] |  |
Sales | 55 | 114
Total Pharmaceutical segment sales | Operating Segments | Zetia |  |
Segment Reporting Information [Line Items] |  |
Sales | 145 | 140
Total Pharmaceutical segment sales | Operating Segments | Vytorin |  |
Segment Reporting Information [Line Items] |  |
Sales | 53 | 97
Total Pharmaceutical segment sales | Operating Segments | Atozet |  |
Segment Reporting Information [Line Items] |  |
Sales | 122 | 94
Total Pharmaceutical segment sales | Operating Segments | Adempas |  |
Segment Reporting Information [Line Items] |  |
Sales | 56 | 48
Total Pharmaceutical segment sales | Operating Segments | Alliance revenue - Adempas (2) |  |
Segment Reporting Information [Line Items] |  |
Sales | 53 | 42
Total Pharmaceutical segment sales | Operating Segments | Januvia |  |
Segment Reporting Information [Line Items] |  |
Sales | 774 | 824
Total Pharmaceutical segment sales | Operating Segments | Janumet |  |
Segment Reporting Information [Line Items] |  |
Sales | 503 | 530
Total Pharmaceutical segment sales | Operating Segments | Implanon/Nexplanon |  |
Segment Reporting Information [Line Items] |  |
Sales | 195 | 199
Total Pharmaceutical segment sales | Operating Segments | NuvaRing |  |
Segment Reporting Information [Line Items] |  |
Sales | 63 | 219
Total Pharmaceutical segment sales | Operating Segments | Singulair |  |
Segment Reporting Information [Line Items] |  |
Sales | 155 | 191
Total Pharmaceutical segment sales | Operating Segments | Cozaar/Hyzaar |  |
Segment Reporting Information [Line Items] |  |
Sales | 102 | 103
Total Pharmaceutical segment sales | Operating Segments | Nasonex |  |
Segment Reporting Information [Line Items] |  |
Sales | 71 | 96
Total Pharmaceutical segment sales | Operating Segments | Arcoxia |  |
Segment Reporting Information [Line Items] |  |
Sales | 70 | 75
Total Pharmaceutical segment sales | Operating Segments | Follistim AQ |  |
Segment Reporting Information [Line Items] |  |
Sales | 41 | 57
Total Pharmaceutical segment sales | Operating Segments | Other pharmaceutical (3) |  |
Segment Reporting Information [Line Items] |  |
Sales | 1,194 | 1,082
Total Pharmaceutical segment sales | United States | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Sales | 4,714 | 4,215
Total Pharmaceutical segment sales | United States | Operating Segments | Keytruda |  |
Segment Reporting Information [Line Items] |  |
Sales | 1,906 | 1,284
Total Pharmaceutical segment sales | United States | Operating Segments | Alliance revenue - Lynparza (1) |  |
Segment Reporting Information [Line Items] |  |
Sales | 85 | 50
Total Pharmaceutical segment sales | United States | Operating Segments | Alliance revenue - Lenvima (1) |  |
Segment Reporting Information [Line Items] |  |
Sales | 90 | 50
Total Pharmaceutical segment sales | United States | Operating Segments | Emend |  |
Segment Reporting Information [Line Items] |  |
Sales | 5 | 63
Total Pharmaceutical segment sales | United States | Operating Segments | Gardasil/Gardasil 9 |  |
Segment Reporting Information [Line Items] |  |
Sales | 461 | 362
Total Pharmaceutical segment sales | United States | Operating Segments | ProQuad/M-M-R II/Varivax |  |
Segment Reporting Information [Line Items] |  |
Sales | 333 | 343
Total Pharmaceutical segment sales | United States | Operating Segments | Pneumovax 23 |  |
Segment Reporting Information [Line Items] |  |
Sales | 182 | 125
Total Pharmaceutical segment sales | United States | Operating Segments | RotaTeq |  |
Segment Reporting Information [Line Items] |  |
Sales | 140 | 154
Total Pharmaceutical segment sales | United States | Operating Segments | Vaqta |  |
Segment Reporting Information [Line Items] |  |
Sales | 30 | 29
Total Pharmaceutical segment sales | United States | Operating Segments | Bridion |  |
Segment Reporting Information [Line Items] |  |
Sales | 143 | 119
Total Pharmaceutical segment sales | United States | Operating Segments | Noxafil |  |
Segment Reporting Information [Line Items] |  |
Sales | 8 | 91
Total Pharmaceutical segment sales | United States | Operating Segments | Invanz |  |
Segment Reporting Information [Line Items] |  |
Sales | 6 | 14
Total Pharmaceutical segment sales | United States | Operating Segments | Prevymis |  |
Segment Reporting Information [Line Items] |  |
Sales | 26 | 18
Total Pharmaceutical segment sales | United States | Operating Segments | Cancidas |  |
Segment Reporting Information [Line Items] |  |
Sales | 3 | 1
Total Pharmaceutical segment sales | United States | Operating Segments | Primaxin |  |
Segment Reporting Information [Line Items] |  |
Sales | 0 | 0
Total Pharmaceutical segment sales | United States | Operating Segments | Cubicin |  |
Segment Reporting Information [Line Items] |  |
Sales | 15 | 42
Total Pharmaceutical segment sales | United States | Operating Segments | Zerbaxa |  |
Segment Reporting Information [Line Items] |  |
Sales | 20 | 12
Total Pharmaceutical segment sales | United States | Operating Segments | Simponi |  |
Segment Reporting Information [Line Items] |  |
Sales | 0 | 0
Total Pharmaceutical segment sales | United States | Operating Segments | Remicade |  |
Segment Reporting Information [Line Items] |  |
Sales | 0 | 0
Total Pharmaceutical segment sales | United States | Operating Segments | Belsomra |  |
Segment Reporting Information [Line Items] |  |
Sales | 27 | 24
Total Pharmaceutical segment sales | United States | Operating Segments | Isentress/Isentress HD |  |
Segment Reporting Information [Line Items] |  |
Sales | 75 | 108
Total Pharmaceutical segment sales | United States | Operating Segments | Zepatier |  |
Segment Reporting Information [Line Items] |  |
Sales | 18 | 33
Total Pharmaceutical segment sales | United States | Operating Segments | Zetia |  |
Segment Reporting Information [Line Items] |  |
Sales | (2) | 0
Total Pharmaceutical segment sales | United States | Operating Segments | Vytorin |  |
Segment Reporting Information [Line Items] |  |
Sales | 3 | 3
Total Pharmaceutical segment sales | United States | Operating Segments | Atozet |  |
Segment Reporting Information [Line Items] |  |
Sales | 0 | 0
Total Pharmaceutical segment sales | United States | Operating Segments | Adempas |  |
Segment Reporting Information [Line Items] |  |
Sales | 0 | 0
Total Pharmaceutical segment sales | United States | Operating Segments | Alliance revenue - Adempas (2) |  |
Segment Reporting Information [Line Items] |  |
Sales | 49 | 40
Total Pharmaceutical segment sales | United States | Operating Segments | Januvia |  |
Segment Reporting Information [Line Items] |  |
Sales | 355 | 384
Total Pharmaceutical segment sales | United States | Operating Segments | Janumet |  |
Segment Reporting Information [Line Items] |  |
Sales | 113 | 167
Total Pharmaceutical segment sales | United States | Operating Segments | Implanon/Nexplanon |  |
Segment Reporting Information [Line Items] |  |
Sales | 149 | 149
Total Pharmaceutical segment sales | United States | Operating Segments | NuvaRing |  |
Segment Reporting Information [Line Items] |  |
Sales | 26 | 185
Total Pharmaceutical segment sales | United States | Operating Segments | Singulair |  |
Segment Reporting Information [Line Items] |  |
Sales | 5 | 5
Total Pharmaceutical segment sales | United States | Operating Segments | Cozaar/Hyzaar |  |
Segment Reporting Information [Line Items] |  |
Sales | 7 | 4
Total Pharmaceutical segment sales | United States | Operating Segments | Nasonex |  |
Segment Reporting Information [Line Items] |  |
Sales | 6 | (1)
Total Pharmaceutical segment sales | United States | Operating Segments | Arcoxia |  |
Segment Reporting Information [Line Items] |  |
Sales | 0 | 0
Total Pharmaceutical segment sales | United States | Operating Segments | Follistim AQ |  |
Segment Reporting Information [Line Items] |  |
Sales | 21 | 29
Total Pharmaceutical segment sales | United States | Operating Segments | Other pharmaceutical (3) |  |
Segment Reporting Information [Line Items] |  |
Sales | 409 | 328
Total Pharmaceutical segment sales | International | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Sales | 5,941 | 5,448
Total Pharmaceutical segment sales | International | Operating Segments | Keytruda |  |
Segment Reporting Information [Line Items] |  |
Sales | 1,378 | 985
Total Pharmaceutical segment sales | International | Operating Segments | Alliance revenue - Lynparza (1) |  |
Segment Reporting Information [Line Items] |  |
Sales | 60 | 29
Total Pharmaceutical segment sales | International | Operating Segments | Alliance revenue - Lenvima (1) |  |
Segment Reporting Information [Line Items] |  |
Sales | 38 | 24
Total Pharmaceutical segment sales | International | Operating Segments | Emend |  |
Segment Reporting Information [Line Items] |  |
Sales | 38 | 53
Total Pharmaceutical segment sales | International | Operating Segments | Gardasil/Gardasil 9 |  |
Segment Reporting Information [Line Items] |  |
Sales | 636 | 476
Total Pharmaceutical segment sales | International | Operating Segments | ProQuad/M-M-R II/Varivax |  |
Segment Reporting Information [Line Items] |  |
Sales | 102 | 153
Total Pharmaceutical segment sales | International | Operating Segments | Pneumovax 23 |  |
Segment Reporting Information [Line Items] |  |
Sales | 75 | 59
Total Pharmaceutical segment sales | International | Operating Segments | RotaTeq |  |
Segment Reporting Information [Line Items] |  |
Sales | 82 | 57
Total Pharmaceutical segment sales | International | Operating Segments | Vaqta |  |
Segment Reporting Information [Line Items] |  |
Sales | 30 | 18
Total Pharmaceutical segment sales | International | Operating Segments | Bridion |  |
Segment Reporting Information [Line Items] |  |
Sales | 157 | 136
Total Pharmaceutical segment sales | International | Operating Segments | Noxafil |  |
Segment Reporting Information [Line Items] |  |
Sales | 87 | 99
Total Pharmaceutical segment sales | International | Operating Segments | Invanz |  |
Segment Reporting Information [Line Items] |  |
Sales | 59 | 58
Total Pharmaceutical segment sales | International | Operating Segments | Prevymis |  |
Segment Reporting Information [Line Items] |  |
Sales | 33 | 14
Total Pharmaceutical segment sales | International | Operating Segments | Cancidas |  |
Segment Reporting Information [Line Items] |  |
Sales | 52 | 60
Total Pharmaceutical segment sales | International | Operating Segments | Primaxin |  |
Segment Reporting Information [Line Items] |  |
Sales | 51 | 59
Total Pharmaceutical segment sales | International | Operating Segments | Cubicin |  |
Segment Reporting Information [Line Items] |  |
Sales | 31 | 46
Total Pharmaceutical segment sales | International | Operating Segments | Zerbaxa |  |
Segment Reporting Information [Line Items] |  |
Sales | 16 | 14
Total Pharmaceutical segment sales | International | Operating Segments | Simponi |  |
Segment Reporting Information [Line Items] |  |
Sales | 215 | 208
Total Pharmaceutical segment sales | International | Operating Segments | Remicade |  |
Segment Reporting Information [Line Items] |  |
Sales | 88 | 123
Total Pharmaceutical segment sales | International | Operating Segments | Belsomra |  |
Segment Reporting Information [Line Items] |  |
Sales | 53 | 44
Total Pharmaceutical segment sales | International | Operating Segments | Isentress/Isentress HD |  |
Segment Reporting Information [Line Items] |  |
Sales | 170 | 147
Total Pharmaceutical segment sales | International | Operating Segments | Zepatier |  |
Segment Reporting Information [Line Items] |  |
Sales | 37 | 81
Total Pharmaceutical segment sales | International | Operating Segments | Zetia |  |
Segment Reporting Information [Line Items] |  |
Sales | 147 | 140
Total Pharmaceutical segment sales | International | Operating Segments | Vytorin |  |
Segment Reporting Information [Line Items] |  |
Sales | 50 | 94
Total Pharmaceutical segment sales | International | Operating Segments | Atozet |  |
Segment Reporting Information [Line Items] |  |
Sales | 122 | 94
Total Pharmaceutical segment sales | International | Operating Segments | Adempas |  |
Segment Reporting Information [Line Items] |  |
Sales | 56 | 48
Total Pharmaceutical segment sales | International | Operating Segments | Alliance revenue - Adempas (2) |  |
Segment Reporting Information [Line Items] |  |
Sales | 5 | 2
Total Pharmaceutical segment sales | International | Operating Segments | Januvia |  |
Segment Reporting Information [Line Items] |  |
Sales | 419 | 440
Total Pharmaceutical segment sales | International | Operating Segments | Janumet |  |
Segment Reporting Information [Line Items] |  |
Sales | 390 | 364
Total Pharmaceutical segment sales | International | Operating Segments | Implanon/Nexplanon |  |
Segment Reporting Information [Line Items] |  |
Sales | 45 | 50
Total Pharmaceutical segment sales | International | Operating Segments | NuvaRing |  |
Segment Reporting Information [Line Items] |  |
Sales | 37 | 34
Total Pharmaceutical segment sales | International | Operating Segments | Singulair |  |
Segment Reporting Information [Line Items] |  |
Sales | 151 | 186
Total Pharmaceutical segment sales | International | Operating Segments | Cozaar/Hyzaar |  |
Segment Reporting Information [Line Items] |  |
Sales | 95 | 99
Total Pharmaceutical segment sales | International | Operating Segments | Nasonex |  |
Segment Reporting Information [Line Items] |  |
Sales | 65 | 97
Total Pharmaceutical segment sales | International | Operating Segments | Arcoxia |  |
Segment Reporting Information [Line Items] |  |
Sales | 70 | 75
Total Pharmaceutical segment sales | International | Operating Segments | Follistim AQ |  |
Segment Reporting Information [Line Items] |  |
Sales | 21 | 28
Total Pharmaceutical segment sales | International | Operating Segments | Other pharmaceutical (3) |  |
Segment Reporting Information [Line Items] |  |
Sales | 780 | 754
Total Animal Health segment sales | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Sales | 1,214 | 1,025
Total Animal Health segment sales | Operating Segments | Livestock |  |
Segment Reporting Information [Line Items] |  |
Sales | 739 | 611
Total Animal Health segment sales | Operating Segments | Companion Animals |  |
Segment Reporting Information [Line Items] |  |
Sales | 475 | 414
Total Animal Health segment sales | United States | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Sales | 384 | 294
Total Animal Health segment sales | United States | Operating Segments | Livestock |  |
Segment Reporting Information [Line Items] |  |
Sales | 162 | 117
Total Animal Health segment sales | United States | Operating Segments | Companion Animals |  |
Segment Reporting Information [Line Items] |  |
Sales | 222 | 177
Total Animal Health segment sales | International | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Sales | 830 | 731
Total Animal Health segment sales | International | Operating Segments | Livestock |  |
Segment Reporting Information [Line Items] |  |
Sales | 577 | 494
Total Animal Health segment sales | International | Operating Segments | Companion Animals |  |
Segment Reporting Information [Line Items] |  |
Sales | 253 | 237
Other segment sales (4) | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Sales | 23 | 39
Other segment sales (4) | United States | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Sales | 23 | 39
Other segment sales (4) | International | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Sales | $ 0 | $ 0

X
- Definition The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585 + Details
Name: | us-gaap_ProceedsFromSaleOfIntangibleAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_SegmentReportingInformationLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=mrk_InternationalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_KeytrudaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_AlliancerevenueLynparzaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_LenvimaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_EmendMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_GardasilGardasil9Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_ProQuadMMRIIVarivaxMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_Pneumovax23Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_RotateqMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_VaqtaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_BridionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_NoxafilMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_InvanzMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_PrevymisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_CancidasMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_PrimaxinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_CubicinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_ZerbaxaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_SimponiMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_RemicadeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_BelsomraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_IsentressIsentressHDMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_ZepatierMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_ZetiaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_VytorinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_AtozetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_AdempasMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_AllianceRevenueAdempasMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_JanuviaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_JanumetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_ImplanonNexplanonMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_NuvaringMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_SingulairMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_NasonexMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_CozaarHyzaarMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_ArcoxiaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_FollistimAqMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_OtherPharmaceuticalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_LivestockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_CompanionAnimalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |